Sandu Pharmaceuticals appoints Dave & Dave as statutory auditors for five years
- Sandu Pharmaceuticals appointed M/s Dave & Dave as statutory auditors for FY27 to FY31
- Outgoing auditors M/s Dileep and Prithvi completed two five-year terms
- Shareholders approved the move at the AGM held on September 11, 2026
- New firm holds valid peer review certificate until March 31, 2028

*this image is generated using AI for illustrative purposes only.
Sandu Pharmaceuticals appointed M/s Dave & Dave as its statutory auditors for a five-year term covering financial years 2026-27 to 2030-31. The company’s shareholders approved the appointment at their annual general meeting held on September 11, 2026.
The new audit firm will hold office from the conclusion of the 41st AGM until the conclusion of the 46th AGM in 2031. This appointment follows the mandatory rotation of auditors under Section 139(2) of the Companies Act, 2013.
Auditor Transition Details
The tenure of the outgoing statutory auditors, M/s Dileep and Prithvi, expired with the conclusion of the 41st AGM. The firm had completed two consecutive five-year terms as the company’s statutory auditor. Consequently, they were ineligible for reappointment.
| Particulars | Details |
|---|---|
| Outgoing Auditors | M/s Dileep and Prithvi (Firm Reg No. 122290W) |
| Incoming Auditors | M/s Dave & Dave (Firm Reg No. 102163W) |
| Term Duration | Five years (FY27 to FY31) |
| Reason for Change | Completion of tenure |
New Auditor Profile
M/s Dave & Dave is a Mumbai-based partnership firm established in 1989. The firm holds Peer Review Certificate No. 020259, valid from March 25, 2025, to March 31, 2028. It comprises two partners, two associates, and ten other staff members.
The firm provides statutory, internal, management, stock, and tax audits. Its partners possess professional experience ranging from 25 to 35 years in taxation, audit, project finance, and GST audit. The firm has served various listed companies, private entities, public sector undertakings, and banking institutions.
Regulatory Compliance
The company disclosed that M/s Dave & Dave is not related to any directors, key managerial personnel, or promoters of Sandu Pharmaceuticals. The change in auditors was made in accordance with the SEBI (Listing Obligations and Disclosures Requirements) Regulations, 2015, and the Companies Act, 2013. No concerns or issues were raised by the outgoing auditors regarding their tenure.
Historical Stock Returns for Sandu Pharmaceuticals
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -2.25% | -5.39% | -7.01% | +5.74% | -22.30% | 0.0% |
How might the transition from M/s Dileep and Prithvi to M/s Dave & Dave impact Sandu Pharmaceuticals' internal control frameworks and audit methodologies?
Given M/s Dave & Dave's extensive experience in banking and project finance, will this influence Sandu Pharmaceuticals' approach to capital structure or debt financing strategies?
Are there any anticipated changes in audit fees or service scope under the new five-year term compared to the previous auditor's tenure?


































